lonidamine has been researched along with Ovarian Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, X; Lv, H; Zhang, Z; Zhou, J | 1 |
| Glickson, JD; Heitjan, DF; Leeper, DB; Nath, K; Nelson, DS; Zhou, R | 1 |
| Amiji, M; Duan, Z; Milane, L | 1 |
| Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Papaldo, P | 1 |
| Brunetti, I; Conte, PF; Dargenio, F; Fanucchi, A; Gadducci, A; Giannessi, PG; Muttini, MP | 1 |
| Bottalico, C; de Lena, M; Guerrieri, A; Lorusso, V; Micelli, G; Palmisano, F | 1 |
| Bottalico, C; Brandi, M; Catino, A; De Lena, M; De Mitrio, A; Gargano, G; Guida, M; Latorre, A; Leone, B; Lorusso, V; Vallejo, C | 1 |
| Bearzatto, A; De Marco, C; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N | 1 |
| Caporusso, L; Catino, A; Crucitta, E; De Lena, M; Fanizza, G; Gargano, G; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D | 1 |
| Costa, A; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N | 1 |
1 review(s) available for lonidamine and Ovarian Neoplasms
| Article | Year |
|---|---|
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Indazoles; Lung Neoplasms; Male; Ovarian Neoplasms; Safety | 2003 |
3 trial(s) available for lonidamine and Ovarian Neoplasms
| Article | Year |
|---|---|
Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Epirubicin; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy | 1994 |
Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Drug Synergism; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms | 1997 |
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
6 other study(ies) available for lonidamine and Ovarian Neoplasms
| Article | Year |
|---|---|
Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arginine; Aspartic Acid; Betulinic Acid; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; Female; Glycine; Humans; Hydrogen-Ion Concentration; Indazoles; Leukocyte Count; Ligands; Mice; Micelles; Oligopeptides; Ovarian Neoplasms; Pentacyclic Triterpenes; Tissue Distribution; Triterpenes; Xenograft Model Antitumor Assays | 2019 |
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.
Topics: Acids; Adenosine Triphosphate; Animals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Synergism; Energy Metabolism; Female; Humans; Hydrogen-Ion Concentration; Indazoles; Intracellular Space; Magnetic Resonance Spectroscopy; Male; Mice, Nude; Monocarboxylic Acid Transporters; Ovarian Neoplasms; Prostatic Neoplasms; Symporters; Xenograft Model Antitumor Assays | 2015 |
Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Resistance, Multiple; ErbB Receptors; Female; Humans; Indazoles; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Polymers | 2011 |
An on-line semi-automated solid-phase extraction procedure for high-performance liquid chromatographic determination of lonidamine in serum.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Humans; Indazoles; Ovarian Neoplasms | 1995 |
Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mitotic Index; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Protamine Kinase; Tubulin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
Topics: Cell Cycle; Cell Survival; Cisplatin; Cross-Linking Reagents; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Female; Humans; In Vitro Techniques; Indazoles; Ovarian Neoplasms; Tumor Cells, Cultured | 1992 |